The market for Highly Potent Active Pharmaceutical Ingredients (HPAPIs) is experiencing significant growth, expected to reach $8.05 billion by 2024 and grow at a CAGR of 10.98% through 2030, primarily due to the anticipated rise in cancer cases globally. As HPAPIs expand beyond cancer treatments into areas like autoimmune diseases and infections, demand for specialized manufacturing capabilities is also increasing. Stricter regulatory guidelines on worker safety and containment are further shaping the landscape, consolidating the market and driving pharmaceutical companies toward partnership with advanced contract manufacturing organizations. The future of the HPAPI market may see the integration of advanced technologies, increased automation, and a broader therapeutic focus, with an emphasis on sustainability and compliance.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.contractpharma.com/why-hpapi-outsourcing-is-surging/
